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Abstract
Unlike vascular endothelial growth factor (VEGF)-A, the effect of
VEGF-C on tumor angiogenesis, vascular permeability, and leukocyte
recruitment is not known. To this end, we quantified in vivo growth and
vascular function in tumors derived from two VEGF-C-overexpressing
(VC1) and mock-transfected cell lines (T241 fibrosarcoma and VEGF-
A2/2 embryonic stem cells) grown in murine dorsal skinfold chambers.
VC1 tumors grew more rapidly than mock-transfected tumors and ex-
hibited parallel increases in tumor angiogenesis. Furthermore, VEGF-C
overexpression elevated vascular permeability in T241 tumors, but not in
VEGF-A2/2 tumors. Surprisingly, unlike VEGF-A, VEGF-C did not in-
crease leukocyte rolling or adhesion in tumor vessels. Administration of
VEGF receptor (VEGFR)-2 neutralizing antibody DC101 reduced vascu-
lar density and permeability of both VC1 and mock-transduced T241
tumors. These data suggest that VEGFR-2 signaling is critical for tumor
angiogenesis and vascular permeability and that VEGFR-3 signaling does
not compensate for VEGFR-2 blockade. An alternate VEGFR, VEGFR-1
or neuropilin-1, may modulate adhesion of leukocytes to tumor vessels.
Introduction
Members of the VEGF4 family are known to stimulate endothelial
cell migration and proliferation (1, 2). To date, six family members
have been identified: VEGF-A, VEGF-B, VEGF-C, VEGF-D, orf-
VEGF (VEGF-E), and PlGF (1–3). Of these, VEGF-A has been
studied most extensively and is known to elevate angiogenesis and
permeability in tumors (1, 2) and to increase leukocyte interaction
with tumor microvessels (4). In contrast, the effect of VEGF-C on
these parameters is not well understood, because direct functional in
vivo studies on the role of VEGF-C have not been performed. In this
study, we tested the hypotheses that VEGF-C increases tumor angio-
genesis, vascular permeability, and leukocyte-endothelial cell interac-
tions and further that these effects can be reversed by VEGFR-2
blockade. We transfected two cell lines, T241 fibrosarcoma and V2
ES cells, with a murine VEGF-C construct. Tumors derived from
these cells were grown in murine dorsal skinfold chambers and
examined by intravital microscopy. VC1 tumors exhibited increased
rates of growth and elevated angiogenesis during the early stages of
growth. In addition, we found that both angiogenesis and vessel
hyperpermeability were reversible by blockade of VEGFR-2. How-
ever, neither VEGF-C overexpression nor VEGFR-2 blockade altered
leukocyte-endothelial cell interactions.
Materials and Methods
Cells and Cell Culture. Amphotropic packaging cell lines Phoenix and
293-GPG were provided by Drs. G. P. Nolan (Stanford University Medical
Center, Palo Alto, CA) and Richard Mulligan (Children’s Hospital, Boston,
MA), respectively. T241 murine fibrosarcoma cells were grown in DMEM
(Life Technologies, Inc., Grand Island, NY) supplemented with 2 mM L-
glutamine, penicillin (100 units/ml), streptomycin (100 mg/ml), and 10% fetal
bovine serum (Life Technologies, Inc.) and maintained at 37°C in 5% CO2. V2
ES cells were cultured as described previously (5).
Cloning of VEGF-C. A cDNA encoding full-length mouse VEGF-C
was isolated by reverse transcription-PCR from VEGF-C-transduced cells.
On the basis of the nucleotide sequence of the murine VEGF-C gene (DDB/
EMBL/GenBank accession no. U73620), VEGF-C forward (59-CCCGG-
ATCCAAGCTTCCACCATGGACTTGCTGTGCTTCTTGT-39, incorporating
BamHI and HindIII sites next to the ATG start codon) and VEGF-C reverse
(59-TTTTCTAGAGCGGCCGCTTAGTTCAGATGTGGCCTTTTCCA-39, in-
corporating XbaI and NotI sites next to the TTA stop codon) primers were
designed (restriction sites are italicized). For optimization to Kozak’s context
around the translational start site, the C at position 14 was modified to G (bold
in the VEGF-C forward sequence). PCR amplification resulted in a 1285-bp
fragment of full-length VEGF-C. This fragment was subcloned using the
HindIII-NotI cloning sites of a modified version of the retroviral vector pMMP
(a generous gift from Dr. Mulligan), generated in the laboratory of Dr. Brian
Seed (Massachusetts General Hospital) by eliminating the original HindIII site
and creating new HindIII and NotI sites within the cloning region. The
VEGF-C fragment was also subcloned into the HindIII-NotI cloning sites of
the pPEAK8 mammalian expression vector (a generous gift from Dr. Seed),
generating a pPEAK8-VEGF-C vector.
Creation of VC1 Cell Lines. For stable transduction of VEGF-C, the
pMMP vector construct was converted to the corresponding virus as described
below. Vector DNA was transfected into helper-free, amphotropic packaging
cell lines (Phoenix) and 293-GPG (with similar results) using Ca21-phosphate
transfection in the presence of 25 mM chloroquine. Cultured supernatants from
these cells were then harvested. T241 cells were transduced by direct exposure
to retroviral supernatants to generate VC1 cell lines. MT T241 cell lines
received empty modified pMMP vector. Following transduction, the viability
and number of T241 cells were determined by trypan blue exclusion and
hemacytometer counts, respectively. V2 ES cells were transfected with
pPEAK8-VEGF-C vector by electroporation, generating V2VC1 ES cells.
Cells were harvested at log phase, washed twice in cold PBS, and resuspended
in PBS at a concentration of 1 3 107 cells/ml. ES cell suspension (500 ml) was
added to a cold 4-mm electroporation cuvette containing 10 mg of circular
plasmid DNA. Cells and DNA were mixed and incubated on ice for 5 min.
Subsequently, a 0.275-kV pulse with capacitance of 975 mF was applied using
a Bio-Rad Gene Pulser II. After a 5-min incubation on ice, cells were plated
onto a gelatinized 100-mm culture dish. Two days after plating, 2 mg/ml
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puromycine were added for selection. Resistant colonies were picked 2 weeks
after electroporation.
Stability of VEGF-C Overexpression. To verify that stable overexpres-
sion of VEGF-C was maintained in tumors during the experiment, Northern
blot analysis was performed. A 391-bp mouse VEGF-C cDNA probe was
generated by PCR using pMMP-VEGF-C as the template (primers: forward,
59-CAGCACAGGTTACCTCAGCAAGACG; reverse, 59-GGGTCCACAAC-
TAGATGGCCGAAGC) and used to probe for VEGF-C gene expression.
Total RNA was isolated from homogenized MT, VC1, V2, and V2VC1
tumors grown in vivo using Ultraspec RNA reagent (BiotechX, Houston, TX)
or TRIzol reagent (Life Technologies, Inc.). Hybridization probes were pre-
pared with a random-primed synthesis kit (Rediprime; Amersham Pharmacia
Biotech, Piscataway, NJ). Blots were hybridized overnight at 65°C, washed at
high stringency (0.13 SCC/1% SDS at 65°C), and exposed on Kodak X-
OMAT film.
Determination of VEGF-A Protein Level. Frozen T241 VC1 and MT
tumors (see below) were homogenized in lysis buffer, and total protein was
extracted using standard techniques. Total protein was quantified (Bio-Rad DC
protein assay kit) according to manufacturer’s instructions. ELISA for
VEGF-A was performed using the Quantikine M VEGF-A Immunoassay kit
(R&D Systems, Minneapolis, MN) following the manufacturer’s instructions.
Mouse VEGF-A protein included with the kit was used as an internal standard.
Reported VEGF-A levels were normalized to the total protein in each sample.
Tumor Model. Dorsal skinfold chambers were surgically implanted in
SCID mice of ;30 g of body weight as reported previously (6). Animals were
allowed 2–3 days to recover from surgery. Subsequently, 2 ml of dense
suspension (containing 2 3 105 T241 VC1 or MT tumor cells, or V2VC1 or
V2 ES cells) were injected into the striated muscle layer of the remaining s.c.
tissue (6). Tumors were excised when they filled the chamber (surface area of
;75 mm2), immediately snap-frozen in liquid nitrogen, and stored at 270°C
for molecular and protein analysis. An additional set of T241 VC1 and MT
tumors was harvested before the end point of the study (day 10 of tumor
growth) for VEGF-A ELISA.
Intravital Microscopy. Tumor-bearing animals were anesthetized with a
mixture of ketamine and xylazine, placed on a microscope stage (Zeiss
Axioplan), and observed under high power. Using FITC-dextran contrast-
enhancement (Sigma Chemical Co.; molecular weight, 2,000,000; 10 mg/ml),
images of tumor microvessels were acquired with an Intensified Charged
Coupled Device (ICCD) camera (AVC D7; Sony, Tokyo, Japan) and digitized
on a Macintosh 8100 computer with NIH image software (version 1.6). Tumor
surface area, the area of the top surface of the tumor within the dorsal chamber,
and VD, the average vessel volume contained in five high-power fields of the
tumor, were measured off-line as described previously (7). The vascular
permeability coefficient was measured using cyanine-5 (Amersham Pharmacia
Biotech)-labeled BSA (Sigma Chemical Co.), as described previously (8). For
visualization of leukocyte-endothelial cell interactions, animals received i.v.
injections of 20 ml of 0.1% rhodamine 6-G (Sigma Chemical Co.) in 0.9%
saline and images were videotaped (S-VHS VCR model SVO-9500 MD;
Sony) for off-line analysis. RBC velocity was measured using temporal cor-
relation velocimetry, and microvessel shear rates were calculated as described
in Ref. 6. The total leukocyte flux (Nt), number of rolling (Nr), and number of
adherent (Na) leukocytes along 100-mm segments of converging vessels were
counted over 30 s (8). Adherent leukocytes were classified as those that
remained stationary for .10 s.
VEGFR-2 Blockade. Intravital microscopy was performed in T241 VC1-
or MT-tumor bearing animals treated with the rat antimouse VEGFR-2 func-
tion-blocking mAb DC101 (9). DC101 mAb (1.2 mg; ImClone, Inc.) was
administered i.p. every 3 days (7), immediately following the intravital mi-
croscopy measurement for that day. Tumors were size-normalized (i.e., the BL
tumor size for both VC1 and MT ranged between 50 and 60 mm2). Most
tumors grew to fill the visible part of the dorsal chamber (surface area of ;75
mm2) 3 days after the initiation of treatment. Hence, a two-dimensional area
was not measurable beyond this point. A separate group of control animals
bearing MT and VC1 tumors were treated with control mAb (1.2 mg, rat IgG
against mouse IgA; ImClone, Inc.) on the same treatment schedule. Tumors
were rapidly harvested following the last intravital microscopy measurement,
snap-frozen, and stored at 270°C for molecular analysis. Because of their slow
growth and the limited lifetime of the dorsal skinfold chamber, VEGFR-2
blockade experiments were not performed on V2VC1 or V2 tumor-bearing
animals.
Statistics. Population means were tested for significant differences by the
two-tailed Student’s t test. Significance was assumed when P , 0.05. All data
are presented as mean 6 SEM unless otherwise noted.
Results and Discussion
VEGF-C RNA Is Elevated in VC1 Tumors. Northern analysis of
T241 VC1 and MT tumor lysates using equal amounts of RNA in
each lane and equal exposure times yielded the two bands expected
with the pMMP-based construct in VC1 but not MT tumors (Fig. 1,
left). The pMMP vector (Maloney full GAG vector-based) generates
two RNA transcripts as a result of alternative splicing outside the
VEGF-C construct. Although both transcripts contain the full-length
VEGF-C cDNA, translation of the shorter species is typically more
efficient (10). Northern analysis of V2VC1 tumor lysates yielded a
single band of ;1.8 kb, as expected with the pPEAK8-based construct
(Fig. 1, right). Western blot analysis showed a result consistent with
overproduction of VEGF-C by T241 VC1 cell and tumor lysates (data
not shown).
VEGF-C Overexpression Augmented Tumor Angiogenesis,
Vascular Permeability, and Growth. VEGF-C has been shown to
mediate vascular function in nonneoplastic settings, including in vitro
capillary endothelial cell proliferation and migration, in vivo angio-
genesis (11), and vascular permeability (12). In this study, T241
tumors overexpressing VEGF-C exhibited a significant increase in
tumor growth and in angiogenesis during the early stages of tumor
growth (Fig. 2, a–d). Quantitative analysis confirmed that T241 VC1
tumor surface area was significantly elevated over MT tumors at days
10 and 13 after implantation (Fig. 2e) before reaching the limit of the
assay at day 16. Furthermore, VD, an index of angiogenesis, exhibited
an ;4-fold increase at day 10 in T241 VC1 tumors and a 3-fold
increase at day 13 (Fig. 2f). Both vessel diameter and length were
elevated in T241 VC1 tumors (data not shown). Vascular permeabil-
ity achieved a significant 2-fold increase in T241 VC1 tumors at day
13 (Fig. 2g). Similar increases in tumor angiogenesis and vascular
permeability due to VEGF-C overexpression were also observed in
Fig. 1. Northern analysis of VC1 tumor lysates. Top, VEGF-C mRNA is undetectable
in T241 MT tumors (left). Two bands of 3.4 (top) and 2.4 kb (bottom) are evident between
18S and 28S rRNAs in VC1 tumors, as expected with pMMP vector. These bands
correspond to the full-length transcript and a splice product lacking ;1 kb of viral
non-long terminal repeat regions. VEGF-C mRNA is detectable as a single, 1.8-kb band
in V2VC1 tumors (right), the full-length transcript expected with the pPEAK8 vector.
Bottom, ethidium bromide-stained gels for analysis of total RNA loading and integrity.
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B16F10 melanoma, another rapidly growing tumor line (data not
shown).
To determine whether endogenous VEGF-A accounted for the
observed differences, ELISA for murine VEGF-A was performed. At
days 10 and 16 of tumor growth, comparable levels of VEGF-A
protein were observed in T241 VC1 and MT tumors. MT tumors
contained 294 6 64 pg/mg VEGF-A at day 10 and 347 6 58 pg/mg
at day 16, whereas VC1 tumors contained 350 6 47 pg/mg VEGF-A
at day 10 and 394 6 84 pg/mg at day 16. Differences were not
significant between the groups at either time point.
Although significant differences in vascular function were observed
between T241 VC1 and MT tumors during early growth (time-
matched comparison), comparison of functional parameters in size-
matched T241 VC1 and MT tumors yielded no significant difference
between the two groups. Therefore, we hypothesized that the effects
of VEGF-C may be dependent on VEGF-A protein level or tumor
growth rate. Hence, we may have been unable to detect differences in
functional parameters in size-matched T241 tumors due to their rapid
growth or the influence of tumor-derived VEGF-A. To test this
hypothesis, we studied the effects of VEGF-C on slowly growing
teratomas derived from V2 ES cells. A prior study of V2 teratomas
indicated that they contain 50% of VEGF-A found in wild-type
teratomas (presumably produced by host cells within the tumor), grow
slower, and exhibit lower vascular density, permeability, and leuko-
cyte adhesion (4). Our data show that overexpression of VEGF-C in
V2 cells was able to partially “rescue” the V2 phenotype. Differences
in tumor growth rate between V2VC1 and control tumors during
early stages of growth were quite pronounced (Fig. 2h), and time-
matched analysis during the early growth rate was not possible for this
reason. However, size-matched analysis showed that V2VC1 tumors
exhibited significantly elevated VD during the early stages of growth
(25 mm2 and 50 mm2). Vascular permeability of V2VC1 tumors,
however, was not significantly elevated at any measured size (Fig. 2,
i–j). Hence, in the teratomas, which grew much more slowly than the
T241 fibrosarcomas, similar effects on tumor angiogenesis were ob-
served on VEGF-C overexpression even under size-matched analysis.
Collectively, our data support the hypothesis that differences in levels
of VEGF-C, not only in VEGF-A, can account for increases in tumor
growth and facilitate tumor angiogenesis (13, 14). The effects of
VEGF-C on tumor vascular permeability, however, remain unclear
and are discussed further below.
Blockade of VEGFR-2 Reversed Angiogenesis. Whereas
VEGF-A binds VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR),
VEGF-C binds VEGFR-2 and VEGFR-3 (flt-4; Ref. 3). Although
VEGFR-2 signaling dominates VEGF-A function, it is not clear which
receptor is important for VEGF-C-induced angiogenesis. The mAb
DC101 specifically binds murine VEGFR-2.5 Here, we show that
administration of DC101 to mice bearing established, size-matched
T241 VC1 and MT tumors elicited significant vessel regression (Fig.
3, a and b). Although the size of tumors in all four groups increased
slightly (Fig. 3c), the limit of the assay (75 mm2) does not allow us to
fully interpret the effect of VEGFR-2 blockade on tumor growth. VD
in both DC101-treated groups was significantly lower than IgG-
treated groups by 6 days after initiation of treatment (Fig. 3d, D6). In
the IgG-treated groups, VD continued to increase beyond BL, achiev-
ing significance at D3 for both IgG groups; however, in the DC101-
treated groups, VD became lower than BL and undetectable at later
time points. No significant difference in VD was observed between
established, size-matched DC101-treated MT and VC1 groups at any
time point regardless of the treatment. Collectively, our data implicate
VEGFR-2 as a primary mediator of tumor angiogenesis, confirming
earlier reports (1–3). Although we found detectable levels of
VEGFR-3 in our tumors by reverse transcription-PCR (data not
shown), the VEGF-C-VEGFR-3 pathway did not rescue angiogenesis
after DC101 treatment.
In summary, although significant efforts, to date, have focused on
blockade of VEGF-A and its receptors as a means of antiangiogenic
therapy, our data collectively suggest that blockade of VEGFR-2,
which binds both VEGF-A and VEGF-C, may be superior to blockade
of VEGF-A alone in the treatment of tumors. Furthermore, the rapid
vascular regression we observed in both tumor groups may be a result
of blockade of both VEGF-A and VEGF-C signaling via VEGFR-2.
In light of recent data showing that administration of soluble
VEGFR-3 reduces angiogenesis mediated by VEGF-C via VEGFR-2
5 D. J. Hicklin, personal communication.
Fig. 2. Rapid-onset angiogenesis and growth in VC1 tumors. a-d, two-dimensional
growth and angiogenesis of T241 MT and VC1 tumors 13 days after implant in the dorsal
skinfold chamber, with FITC-dextran contrast enhancement of microvessels (a and b) or
low-power transillumination (c and d). MT tumors (a and c) exhibit relatively little
growth, as the tumor boundary is visible within the image (arrows), and vessels are of
relatively small diameter. In contrast, VC1 tumors (b and d) exhibit significant growth, as
the tumor boundary is not visible within the image, and several vessels of relatively large
diameter are evident. Bars, 50 mm (a and b) and 250 mm (c and d). e-j, quantification of
functional vascular parameters. e, two-dimensional surface area of T241 VC1 tumors rose
significantly faster than MT tumors over the measurement period. f, VD, an index of
angiogenesis, was 4-fold greater in VC1 tumors than MT tumors at D10 and 3-fold greater
at D13. g, vascular permeability was significantly higher in VC1 tumors at D13. h,
two-dimensional surface area of tumors derived from V2VC1 ES cells increased signif-
icantly faster than that of tumors derived from V2 ES cells at early stages of growth.
Furthermore, the mean total time required for tumors to fill the visible area of the dorsal
chamber (area, 75 mm2) was significantly lower in V2VC1 tumors (26 6 4.2 days versus
45 6 3.4 days, P , 0.01). i, VD in V2VC1 tumors was significantly elevated at smaller
sizes. j, no significant differences in vascular permeability were observed between
V2VC1 and V2 tumors, but permeability in V2VC1 tumors trended higher at all
measured sizes. M, T241 MT or V2; f, T241 VC1 or V2VC1; p, P , 0.05 as compared
with corresponding MT tumors (n 5 5–7 animals for T241, 4–6 for ES).
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(15), we propose that the quantity of VEGFR-3 present on the tumor
vascular endothelium may be critical to tumor angiogenesis facilitated
by the VEGF-C-VEGFR-2 pathway. This possibility remains to be
explored.
Blockade of VEGFR-2 Reversed Vascular Hyperpermeability.
Elevated permeability is a hallmark of tumor microvasculature (16–
18). The VEGF family, and VEGF-A in particular, is known to
mediate the hyperpermeability of tumor vessels (1–3). A role for
VEGF-C in modulating vascular permeability has been demonstrated
in vitro and via Miles assay in vivo (12, 19). Furthermore, VEGF-C
has been shown to act synergistically with VEGF-A to induce degra-
dation of matrix components (14) and angiogenesis in vitro (15). In
our study, BL vascular permeability was significantly greater in T241
VC1 tumors than in MT tumors (Fig. 3e), but permeability in both
VC1 tumors and MT tumors declined to the levels of normal vessels
(;5 3 10-8 cm/s) 3 days after the initiation of DC101 treatment.
Furthermore, these levels were maintained for the remainder of the
study. Permeability could not be measured at D9 in treated MT tumors
because functional vessels could not be detected (Fig. 3d). No differ-
ence in vascular permeability was observed between established,
size-matched IgG-treated VC1 and MT tumors at any time point
following the initiation of IgG administration, but permeability in both
IgG-treated groups was significantly greater than DC101-treated
groups. These findings suggest that tumor microvascular permeability
is predominantly mediated by VEGFR-2 in our model.
The vascular permeability of MT tumors, presumably a result of
VEGF-A (16, 18), decreases to the limit of detection following
VEGFR-2 blockade. The functional data derived from our time-
matched and size-matched analysis of T241 tumors (Figs. 2g and 3e)
suggest that VEGF-C overexpression increases vascular permeability
beyond that induced by VEGF-A alone. However, the V2 tumor
permeability data (Fig. 2j) argue against this hypothesis. The relative
difference in VEGF-C protein expression between T241 VC1 and
V2VC1 tumors is unknown due to the lack of sufficiently sensitive
quantitative assays; hence, the possibility exists that the discrepancy is
a simple result of increased VEGF-C production by T241 VC1
tumors. However, if the tumors produce similar levels of VEGF-C,
three alternate explanations of this discrepancy are also consistent
with our data. First, VEGF-C may act directly to increase vascular
permeability via VEGFR-2, independently of VEGF-A. Second,
VEGF-A and VEGF-C may act synergistically via VEGFR-2 (14). In
this case, we would expect a decreased permeability in MT tumors
after VEGFR-2 blockade mainly due to loss of VEGF-A-VEGFR-2
signal, but would expect VC1 tumor permeability to decrease to a
greater extent due to loss of both synergy and VEGF-A signaling.
Third, VEGF-C may potentiate VEGF-A-VEGFR-2-induced in-
creases in vascular permeability via VEGFR-3. The VEGF-C-
VEGFR-3 effect, however, may not be observed in the absence of the
VEGFR-2 signaling pathway, and blockade of VEGFR-2 would, thus,
completely eliminate hyperpermeability. A quantification of vascular
permeability in normal tissue treated with variable quantities of
VEGF-C and VEGF-A protein may illuminate the interplay between
these growth factors in the modulation of tumor vascular permeability.
VEGF-C Overexpression Did Not Affect Leukocyte-Endothe-
lial Cell Interactions. Inflammatory cytokines induce VEGF-C ex-
pression, and it has been proposed that this may influence lymphocyte
Fig. 3. Effects of VEGFR-2 blockade by DC101
mAb administration. Five to seven T241 tumors in
each group were size-matched at BL, and treatment
with DC101 or control IgG was begun. Analysis
was performed every 3 days after treatment onset
(D3, D6, and D9). a and b, representative transil-
lumination images of the same tumor 3 days (a)
and 6 days (b) after DC101 treatment. a, normal
tissue is seen outside the tumor boundary (arrow),
along with distinct vasculature. Significant vascular
regression has occurred in b, but tumor growth has
continued to a maximum quantifiable size. A large,
avascular area is visible toward the tumor center (b,
arrow; bar, 500 mm). c, tumor growth in all groups
continued normally after DC101 administration up
to D3. After D6, tumors of all groups filled the
dorsal window, maximum measurable area of
which is 75 mm2 (dashed line), precluding further
quantification of growth beyond this size. d, VD
was not significantly different between the DC101-
treated VC1 and MT tumors up to D3. However,
VD in both DC101-treated tumor groups was sig-
nificantly lower than IgG-treated tumor groups at
D6 and D9 (†, P , 0.01). In the IgG-treated
groups, VD became significantly greater than BL at
D3 (p, P , 0.05) and continued to increase to the
study end point. e, vascular permeability was ;2-
fold higher in VC1 tumors relative to their respec-
tive MT controls at BL (p, P , 0.05). Permeability
in DC101-treated tumor groups exhibited a sharp
reduction by D3, and was significantly decreased
compared with IgG-treated groups at all successive
time points (†, P , 0.05, all) but not significantly
different from the MT BL level.
Table 1 Leukocyte-endothelial cell interactions in T241 VC1 and MT tumors
Groupa Tumor typeb Nt (cells/30 s)c Nr (%)d Na (cells/mm2)e
BL MT 8.0 6 1.4 22.3 6 4.6 75.7 6 39.9
VC1 9.0 6 1.5 17.4 6 3.5 63.2 6 43.9
D3 MT DC101 11.0 6 1.6 19.3 6 3.4 146.3 6 46.7
VC1 DC101 6.0 6 1.6 14.3 6 4.4 80.1 6 65.6
MT IgG 8.5 6 1.8 15.0 6 6.1 95.3 6 47.5
VC1 IgG 9.0 6 2.1 20.4 6 3.6 112.4 6 51.4
D6 MT DC101 14.0 6 2.6 14.7 6 4.0 137.9 6 37.9
VC1 DC101 11.0 6 2.0 19.7 6 4.7 143.1 6 56.0
MT IgG 13.5 6 1.8 15.8 6 3.9 85.5 6 51.4
VC1 IgG 16.0 6 2.0 18.5 6 5.1 101.3 6 61.9
a D3, 3 days post-DC101 treatment initiation; D6, 6 days post-DC101 treatment
initiation.
b DC101, DC101-treated; IgG, nonspecific rat IgG-treated.
c Total leukocyte flux/30 s.
d Percentage of rolling leukocytes.
e Number of adherent leukocytes/mm2. Data are mean 6 SEM.
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trafficking in inflammation (20). However, the effects of VEGF-C on
leukocyte recruitment and adhesion to endothelium have not been
characterized, to date. In contrast to other parameters associated with
angiogenesis, we found that leukocyte-endothelial interactions as
characterized by total leukocyte flux, rolling percentage, and adhesion
density were not significantly different between size-matched T241
VC1 and MT tumors before or after treatment with DC101 (Table 1),
in age-matched T241 VC1 and MT tumors (data not shown) or in
size-matched V2 teratomas (data not shown). DC101-treated tumors
did not exhibit significantly different leukocyte-endothelial interac-
tions compared with the IgG-treated groups (Table 1). Microvessel
shear rates were not significantly different between any groups (data
not shown). Interestingly, VEGF-C sufficient to produce significant
and detectable increases in vascular permeability (compared with
normal tissue) seemed to be present in BL VC1 tumors (Fig. 3e), but
the same VEGF-C expression did not produce a detectable increase in
leukocyte recruitment. Furthermore, in V2VC1 tumors that contain
;50% of control tumor VEGF-A (4), no detectable increase in leu-
kocyte recruitment is observed (data not shown), suggesting that
VEGF-C alone does not mediate leukocyte-endothelium interaction.
In light of data demonstrating that VEGF-A may recruit leukocytes to
sites of inflammation via up-regulation of endothelial intercellular
adhesion molecule-1 or vascular cell adhesion molecule-1 (21), these
observations further suggest that leukocyte adhesion molecule up-
regulation may be modulated via a receptor other than VEGFR-2,
such as VEGFR-1 (flt-1) or neuropilin-1 (22). However, detectable
effects on leukocyte recruitment following VEGFR-2 blockade may
not have been observed because of low BL leukocyte infiltration in
these tumors. These possibilities remain to be explored. In conclusion,
given the wide variety of human tumors known to express VEGF-C
(3, 23), our findings suggest that VEGF-C may play a critical role in
the angiogenesis, hyperpermeability, and growth of human tumors.
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